Hyperkalaemia: ECG risk, emergency stabilisation and potassium removal

Clinical scope and immediate priorities

Hyperkalaemia can cause fatal arrhythmia, but risk is not determined by the potassium concentration alone. Rate of rise, ECG changes, kidney function, acidosis and concurrent conduction disease all matter. A severely elevated result should be treated as potentially genuine while pseudohyperkalaemia is checked in parallel when clinically plausible. Kidney disease changes fluid, electrolyte and medication handling across almost every specialty. Trends are often more informative than a single creatinine or electrolyte result. Volume status, urine findings, nephrotoxic exposures, obstruction, acid-base status and the tempo of change should be considered together, with early specialist escalation when complications become difficult to control.

Recognition and differential diagnosis

Many patients are asymptomatic. Weakness, paraesthesia, palpitations or bradycardia can occur. ECG changes progress variably from peaked T waves and PR prolongation to QRS widening, sine-wave morphology and arrest; a normal ECG does not make severe hyperkalaemia safe. The practical aim is to identify features that change urgency, distinguish common mimics and avoid anchoring on a single test result. Where the presentation is atypical, reassess the working diagnosis rather than forcing the findings to fit it.

Assessment and investigations

Repeat a non-haemolysed sample when pseudohyperkalaemia is possible without delaying treatment in a high-risk patient. Review kidney function, acid-base status, glucose and medicines such as renin-angiotensin blockers, mineralocorticoid antagonists, potassium supplements, trimethoprim and NSAIDs. Consider tissue breakdown, adrenal insufficiency and uncontrolled diabetes. Investigations should be sequenced so that urgent bedside information is obtained first, followed by tests that refine cause, severity or treatment choice. Trends, prior results and treatment effects often matter more than whether one value sits just inside or outside a reference range.

Initial and definitive management

Give intravenous calcium promptly for significant ECG changes or peri-arrest risk to stabilise the myocardium. Shift potassium intracellularly with insulin and glucose, with inhaled beta-agonist as an adjunct where appropriate; bicarbonate has a limited role except in selected severe metabolic acidosis. Remove potassium through diuresis, gastrointestinal potassium binders or dialysis according to context, and stop ongoing potassium loading. Treatment should address reversible causes and immediate physiological risk while preserving options for definitive care. Medication selection requires attention to allergies, interactions, renal or hepatic function, pregnancy where relevant, and the possibility that a medicine suitable in one health system may not be first-line in another.

Escalation, complications and special situations

Refractory severe hyperkalaemia, oliguria, major ECG abnormalities or recurrent rebound requires urgent nephrology/critical-care input and possible dialysis. Continuous cardiac monitoring is appropriate when arrhythmic risk is significant. Escalate early when instability, organ dysfunction, rapidly progressive symptoms or a high-risk comorbidity is present. Frailty, pregnancy, immunosuppression, extremes of age and major renal or hepatic impairment can alter both presentation and treatment tolerance, so protocol-based care still requires individualisation.

International practice across English-speaking health systems

Across the United Kingdom, United States, Canada, Australia, New Zealand and Ireland, the core clinical principles are broadly similar, but drug licensing, formularies, emergency pathways, screening thresholds, referral criteria and professional scope can differ. Use the most recent national or regional guidance, local antimicrobial or medicines policy, and the relevant product information when an operational detail could change treatment. MDPDA therefore presents a common evidence-based framework and highlights areas that should be adapted locally rather than implying that one country’s pathway is universal.

Monitoring, follow-up and prevention

Follow-up should be purposeful rather than routine. Define what is being monitored, when it should be reassessed and what finding would change management. Review adherence and adverse effects, repeat objective measurements when they inform risk, and reconsider the diagnosis if the clinical course is inconsistent with expectations. Safety-netting should state which symptoms require urgent reassessment and which service should be contacted. For chronic disease, prevention, vaccination where relevant, smoking cessation, nutrition, physical activity and management of related cardiovascular or metabolic risk can be as important as disease-specific treatment. Recheck potassium after temporising therapy because intracellular shift does not remove potassium from the body. Review whether long-term potassium binders or medication adjustments can preserve prognostically beneficial renin-angiotensin system therapy.

Common pitfalls and safety checks

A normal ECG does not exclude dangerous hyperkalaemia. Insulin lowers potassium temporarily and can cause delayed hypoglycaemia. Calcium protects the myocardium but does not lower potassium. Do not permanently stop beneficial cardiorenal therapy without considering strategies to control recurrent potassium elevation. A useful final check is to ask what dangerous alternative diagnosis could still explain the presentation, whether the patient has demonstrated an appropriate response to treatment, and whether the discharge or transfer plan is safe if symptoms recur.

Documentation, communication and shared decisions

Documentation should make the clinical reasoning visible. Record the key positive and negative findings, relevant risk stratification, important investigations, treatment rationale, discussions with the patient or family where appropriate, and the trigger for escalation or review. When care crosses settings, handover should identify unresolved diagnostic questions, medicines started or withheld, pending results and who is responsible for follow-up. Shared decisions are particularly important when more than one reasonable strategy exists or when treatment benefit must be balanced against bleeding, frailty, treatment burden or quality of life.

Implementation across care settings

Kidney-focused implementation requires deliberate medication reconciliation because dosing, nephrotoxicity and electrolyte effects change as renal function changes. Communicate baseline creatinine or eGFR, recent trend, urine findings, volume assessment and the plan for repeat tests. Pharmacists and primary-care teams are essential for avoiding unsafe combinations after discharge. Patients should know which intercurrent illnesses or medicines warrant earlier review. Access to nephrology and dialysis services differs by region, so early consultation is preferable when trajectory suggests that advanced support may be needed.

Quality and patient-safety review

Before closing the episode of care, confirm that the working diagnosis remains consistent with the observed course, that high-risk alternatives have been considered, and that treatment has not introduced a new avoidable hazard. Review allergies, interactions, renal or hepatic constraints, pregnancy considerations where relevant, and the patient’s ability to follow the plan. The safest pathway is one in which the next clinician can understand what has been decided, what remains uncertain and which finding should trigger escalation.

Applying evidence to the individual patient

Guidelines provide a framework, but safe implementation depends on the patient’s baseline function, comorbidities, concurrent medicines, treatment goals and access to follow-up. Recommendations should be interpreted in light of absolute rather than relative benefit where possible, and clinicians should identify when the evidence base under-represents older people, pregnancy, severe kidney or liver impairment, multimorbidity or other groups. When two reasonable options exist, explain the trade-offs and document the reason for the selected approach. If local policy differs from an international recommendation, determine whether this reflects formulary, service configuration, licensing or genuinely different evidence. Reassessment is part of evidence-based care: a working diagnosis or treatment plan that no longer fits the clinical course should be revised rather than defended simply because it matched the initial pathway.

Practical review checklist

Before finalising management, confirm that the severity has been classified correctly, essential investigations have been acted on, and any test still pending has a named clinician or service responsible for review. Reconcile regular medicines and temporary changes, check whether monitoring is required after initiation or dose adjustment, and make the follow-up interval proportionate to risk. Explain the plan in language the patient can use, including what improvement is expected, which adverse effects matter and which symptoms require urgent help. Where care is shared between primary, secondary, dental, pharmacy or community services, avoid ambiguous instructions such as ‘follow up as needed’; specify who should do what and when. This final systems check often prevents harm that is not caused by the clinical decision itself but by gaps in implementation.